Claim Ledger
73% answered
Did management answer the analysts?
11 analyst questions audited, 1 evaded or deflected.
View Claim Ledger →Best Agrolife Limited — Q4 FY26
Best Agrolife reported a weak FY26 with consolidated revenue of ₹1,257 crore, down 31% YoY, and PAT of just ₹9 crore (vs ₹70 crore in FY25).
bearish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Best Agrolife reported a weak FY26 with consolidated revenue of ₹1,257 crore, down 31% YoY, and PAT of just ₹9 crore (vs ₹70 crore in FY25). The Q4 quarter was particularly weak, with revenue of ₹156 crore (down 43% YoY) and an EBITDA loss of ₹27 crore. The decline was driven by adverse weather, elevated channel inventory, and a conscious decision to defer ~₹50-70 crore of sales in March to protect margins amid rising raw material costs. Management highlighted that patented products now contribute 40% of branded sales (up from 30%), and inventory has been reduced from ₹958 crore in FY24 to ₹651 crore. For FY27, they expect gradual recovery supported by two rounds of price increases, new patented product launches, and a shift toward B2B technical sales. Key risks include El Niño impact on the rabi season and continued raw material volatility from the Gulf conflict.
बेस्ट एग्रोलाइफ का FY26 कमजोर रहा। कंपनी की कुल कमाई ₹1,257 करोड़ रही, जो पिछले साल से 31% कम है। मुनाफा सिर्फ ₹9 करोड़ रहा (पिछले साल ₹70 करोड़ था)। खासकर चौथी तिमाही बहुत कमजोर रही - कमाई ₹156 करोड़ (43% गिरावट) और EBITDA में ₹27 करोड़ का घाटा हुआ। इसकी वजहें हैं: खराब मौसम, दुकानों में ज्यादा माल, और मार्च में ₹50-70 करोड़ की बिक्री टालना ताकि कच्चे माल की बढ़ती कीमतों से बचा जा सके। कंपनी ने बताया कि पेटेंट वाले उत्पादों की बिक्री अब ब्रांडेड बिक्री का 40% है (पहले 30% थी)। माल का स्टॉक ₹958 करोड़ से घटाकर ₹651 करोड़ किया गया। FY27 में दो बार कीमत बढ़ोतरी, नए पेटेंट उत्पादों और B2B बिक्री से धीरे-धीरे सुधार की उम्मीद है। जोखिम: अल नीनो का रबी फसल पर असर और खाड़ी संघर्ष से कच्चे माल की कीमतों में उतार-चढ़ाव।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Risks
4 risks
Risk Intelligence
El Niño impact on rabi season
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Patented product share of branded sales
40%
+10pp YoY
Patented products now contribute 40% of branded sales, up from 30% last year, indicating a shift in product mix.
Inventory level
₹651 crore
-₹307 crore vs FY24
Inventory reduced from ₹958 crore in FY24 to ₹651 crore in FY26, reflecting tighter procurement and channel management.
Dealer network size
10,800
flat
Distribution network stands at ~10,800 dealers; management plans to prune non-performing ones.
Sales return percentage
20-21%
-10pp YoY
Sales returns reduced from 30% to ~20-21% due to stricter policies, improving revenue quality.
What Changed vs Last Quarter
NEW
Two rounds of price increases in April and May 2026
Management implemented price hikes in April and May 2026 to offset rising input costs, expected to support profitability from Q1 FY27.
NEW
Launch of three new patented products in FY27
The company plans to launch three new patented products (fluan, bitcoin cubit power extra, and the shampoo) in FY27 to strengthen the specialized crop protection portfolio.
NEW
Target sales return below 20%
Management aims to reduce sales returns to less than 20% in FY27, down from the current 20-21%.
NEW
Capex on hold
New capex at existing plants has been postponed; no major capital expenditure planned in the near term.
DROPPED
FY26 revenue guidance of 1,300-1,400 crore
Management expects full-year FY26 revenue between 1,300 and 1,400 crore, implying Q4 run-rate of 200-300 crore.
DROPPED
FY27 revenue target of 1,500-1,600 crore
For FY27, management targets revenue of 1,500-1,600 crore, driven by patented product growth and stabilization.
DROPPED
EBITDA margin target of 16-17% in FY27
Management expects EBITDA margin to improve to 16-17% in FY27, up from ~11.5% in 9M FY26.
DROPPED
No losses in Q4 FY26
Management aims to report a profit (no losses) in Q4 FY26, despite softer seasonal demand.
NEW RISK
El Niño impact on rabi season
El Niño is expected to kick in between September and October, potentially causing a 2°C+ temperature rise and impacting rabi crops.
NEW RISK
Raw material price volatility from Gulf conflict
The ongoing Gulf conflict has increased prices of solvents and formulations, creating margin pressure.
NEW RISK
High receivables and working capital strain
An analyst raised concerns about receivables of ~₹500 crore (50% of sales) and potential write-offs; management defended by citing seasonal collection patterns.
NEW RISK
Repeated guidance misses eroding investor confidence
An analyst noted that the company has missed guidance multiple times, including Q4 FY26 where losses doubled despite earlier expectations of a small loss or profit.
RISK GONE
Warrant conversion risk at unfavorable price
Outstanding warrants with exercise price of ~42 rupees (post-split) are far above current market price of ~19 rupees, potentially leading to non-exercise and equity dilution or failed capital raise.
RISK GONE
El Niño weather risk for FY27
Potential El Niño conditions could disrupt crop cycles and reduce demand for agrochemicals, impacting revenue recovery plans.
RISK GONE
High interest cost burden
Interest costs of 50-55 crore annually exceed net profits, raising sustainability concerns if profitability does not improve.
RISK GONE
Market share loss in generics
Non-patent portfolio declined 48% in 9M FY26, indicating potential market share loss as company pivots to patented products.
Fast read
Guidance and risk preview
Management implemented price hikes in April and May 2026 to offset rising input costs, expected to support profitability from Q1 FY27.
El Niño is expected to kick in between September and October, potentially causing a 2°C+ temperature rise and impacting rabi crops.
View Risks →